Asston Pharmaceuticals IPO Opens For Subscription From July 9, Check GMP, Price Band & Other Key Details
Mumbai: Asston Pharmaceuticals Limited has launched its Rs 27.56 crore IPO, open for subscription from July 9 to 11. With a price band of Rs 115–Rs 123 per share, the IPO is a fresh issue of 22.41 lakh shares. The company specializes in manufacturing and exporting a wide range of pharmaceutical products globally.
What is the IPO size of Asston Pharmaceuticals?
The IPO is worth Rs 27.56 crore and is a book-built issue. It includes a fresh issue of 22.41 lakh shares with no offer-for-sale portion.
What is the price band and lot size?
The price band is Rs 115 to Rs 123 per share.
1 lot = 1000 shares
Retail investors must apply for at least 2 lots (Rs 2,30,000)
HNI investors must apply for at least 3 lots (Rs 3,69,000)
Allotment and listing dates
IPO opens: July 9
IPO closes: July 11
Allotment date: July 14 (tentative)
Shares in demat: July 15
Listing on BSE SME: Expected July 16
IPO structure and share allocation
Out of 22,41,000 shares:
1,13,000 shares (5.04 percent) for market maker
10,60,000 shares (47.30 percent) for QIBs
3,22,000 shares (14.37 percent) for HNIs/NIIs
7,46,000 shares (33.29 percent) for retail investors
6,35,000 shares (28.34 percent) already allotted to anchor investors
What is the current GMP?
The Grey Market Premium (GMP) is Rs 15, which is 12.2 percent higher than the upper price band of Rs 123.
What does Asston Pharmaceuticals do?
Established in 2019, Asston is a pharma company focused on global exports. It makes and trades tablets, capsules, sachets, and syrups in various therapeutic areas like:
- Painkillers
- Antibiotics
- Antifungals
Vitamins and supplements
It works under its own brand and through contract manufacturing and loan licenses, mainly in a principal-to-principal model. It is certified by Central/State FDAs and NQA, and operates as per QMS standards.
How is the company performing financially?
From FY24 to FY25:
Revenue grew by 62 percent
Profit After Tax (PAT) rose by 218 percent
FY25 Revenue: Rs 6.21 crore
FY25 PAT: Rs 1.32 crore
Purpose of the IPO funds
Funds raised will be used for:
- Buying machinery for its manufacturing unit
- Working capital needs
- Partial or full debt repayment
- General corporate purposes
Who is the lead manager?
Saubhagya Capital Options Ltd is the book-running lead manager for the IPO.
Who is the registrar?
Maashitla Securities Pvt Ltd is the registrar for this IPO.
(Disclaimer: The recommendations, suggestions, views, and opinions expressed by experts are their own and do not represent the views of The Free Press Journal.)
news